Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), announced that its Chairman and CEO, Lishan Aklog, M.D., will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 11:00 AM EDT. The event will be webcast live and accessible via the Investor Relations Section of Lucid Diagnostics' website. A replay will be available for 30 days post-event. During the conference, company management will also engage in one-on-one meetings with investors.
Lucid Diagnostics (Nasdaq: LUCD), una società di diagnostica medica per la prevenzione del cancro in fase commerciale e filiale di PAVmed (Nasdaq: PAVM), ha annunciato che il suo Presidente e CEO, Lishan Aklog, M.D., parteciperà a un fireside chat durante la 24ª Conferenza Virtuale Annuale di Healthcare di Needham il 10 aprile 2025 alle 11:00 AM EDT. L'evento sarà trasmesso in diretta e accessibile tramite la Sezione Relazioni con gli Investitori del sito web di Lucid Diagnostics. Una registrazione sarà disponibile per 30 giorni dopo l'evento. Durante la conferenza, il management dell'azienda parteciperà anche a incontri individuali con gli investitori.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico en etapa comercial para la prevención del cáncer y subsidiaria de PAVmed (Nasdaq: PAVM), anunció que su Presidente y CEO, Lishan Aklog, M.D., participará en un fireside chat en la 24ª Conferencia Virtual Anual de Healthcare de Needham el 10 de abril de 2025 a las 11:00 AM EDT. El evento se transmitirá en vivo y será accesible a través de la Sección de Relaciones con Inversores del sitio web de Lucid Diagnostics. Una repetición estará disponible durante 30 días después del evento. Durante la conferencia, la dirección de la empresa también participará en reuniones uno a uno con los inversores.
Lucid Diagnostics (Nasdaq: LUCD), 상업 단계의 암 예방 의료 진단 회사이자 PAVmed (Nasdaq: PAVM)의 자회사,는 Lishan Aklog, M.D. 회장 겸 CEO가 제24회 니드햄 가상 의료 컨퍼런스에서 파이어사이드 채팅에 참여할 것이라고 발표했습니다. 이 행사는 2025년 4월 10일 오전 11시(EDT)에 열립니다. 이 이벤트는 생중계되며 Lucid Diagnostics 웹사이트의 투자자 관계 섹션을 통해 접근할 수 있습니다. 이벤트 후 30일 동안 다시 보기 기능이 제공됩니다. 컨퍼런스 동안 회사 경영진은 투자자들과 개별 회의도 진행할 예정입니다.
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostics médicaux en phase commerciale pour la prévention du cancer et filiale de PAVmed (Nasdaq: PAVM), a annoncé que son Président et CEO, Lishan Aklog, M.D., participera à un fireside chat lors de la 24e Conférence Virtuelle Annuelle de Santé de Needham le 10 avril 2025 à 11h00 EDT. L'événement sera diffusé en direct et accessible via la section Relations Investisseurs du site Web de Lucid Diagnostics. Un enregistrement sera disponible pendant 30 jours après l'événement. Pendant la conférence, la direction de l'entreprise participera également à des réunions individuelles avec les investisseurs.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen für medizinische Diagnostik zur Krebsprävention in der kommerziellen Phase und Tochtergesellschaft von PAVmed (Nasdaq: PAVM), gab bekannt, dass sein Vorsitzender und CEO, Lishan Aklog, M.D., an einem Fireside Chat auf der 24. jährlichen virtuellen Healthcare-Konferenz von Needham am 10. April 2025 um 11:00 Uhr EDT teilnehmen wird. Die Veranstaltung wird live übertragen und über den Bereich Investor Relations der Website von Lucid Diagnostics zugänglich sein. Eine Wiederholung wird 30 Tage nach der Veranstaltung verfügbar sein. Während der Konferenz wird das Management des Unternehmens auch an Einzelgesprächen mit Investoren teilnehmen.
- None.
- None.
The fireside chat will be webcast live and can be accessed by visiting the Investor Relations Section of the Lucid Diagnostics website or by clicking here. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. Company management will meet with investors in one-on-one meetings during the conference.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-24th-annual-needham-virtual-healthcare-conference-302419513.html
SOURCE Lucid Diagnostics
FAQ
What is the date and time of Lucid Diagnostics' fireside chat at the 24th Annual Needham Virtual Healthcare Conference?
How can I access the live webcast of Lucid Diagnostics' fireside chat?
Will there be a replay available for Lucid Diagnostics' fireside chat?
Who will represent Lucid Diagnostics at the Needham Virtual Healthcare Conference?
What is the stock symbol for Lucid Diagnostics?
